

FDA-Industry GDUFA Reauthorization Meeting
May 13, 2021, 10:00 am – 12:00 pm
Virtual Meeting

Purpose

To continue negotiations to reauthorize GDUFA (GDUFA III).

Participants

FDA

Carter Beach	CDER
Donald Beers	OC/OCC
Lisa Berry	CDER
Ashley Boam	CDER
Joshua Brown	OC/OCC
Jacqueline Corrigan-Curay	CDER
Alonza Cruse	ORA
Robert Lionberger	CDER
Susan Rosencrance	CDER
Bethany Rue	CDER
Edward Sherwood	CDER
Maryll Toufanian	CDER

Industry

John DiLoreto	BPTF
David Gaugh	AAM
Karin Hessler	AAM
Kiran Krishnan	AAM (Apotex)
Brian McCormick	AAM (Teva)
Lisa Parks	AAM
Gil Roth	PBOA
Cornell Stamoran	PBOA (Catalent)
Tom Thorpe	PBOA (Afton Scientific)
Molly Ventrelli	AAM (Fresenius-Kabi)
Brant Zell	BPTF (AmbioPharm)

FDA Supporting Staff

Tiana Barnes, Dat Doan, Andrew Fine, Tawni Schwemer, Scott Vehovic

Discussion

FDA and industry continued discussions around the proposals for setting a sound foundation for continued programmatic success.

FDA introduced a set of proposals around complex generics and will continue these discussions in upcoming meetings.

Next Meeting

The next negotiation meeting will be Thursday, May 20, 2021.